Based on drug class, the Parkinson�s disease treatment market is classified into carbidopa/levodopa, dopamine receptor agonists, MAO-inhibitors, COMT-inhibitors, anticholinergics and other drugs. The carbidopa/levodopa segment is accounted for the largest share in the Parkinson�s disease s treatment market. The growth of this market segment is mainly driven by its potency and wide use in the treatment of Parkinson�s disease.